HBM Healthcare Investments AG

Equities

HBMN

CH0012627250

Investment Management & Fund Operators

Market Closed - Swiss Exchange 12:30:28 2024-03-28 pm EDT 5-day change 1st Jan Change
193.6 CHF -0.41% Intraday chart for HBM Healthcare Investments AG +5.91% +6.02%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
HBM Healthcare Investments AG Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
HBM Healthcare Investments Logs Lower Fiscal Q3 Loss MT
HBM Healthcare Investments Warns of FY24 Nine-month Net Loss MT
AbbVie to Buy Cancer-focused ImmunoGen for $10.1 Billion MT
Kepler Cheuvreux Lowers Price Target on HBM Healthcare Investments, Maintains Buy Recommendation MT
HBM Healthcare Investments Launches Share Buyback MT
HBM Healthcare Investments AG Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
HBM Healthcare Investments Logs Higher Fiscal H1 Loss MT
Tranche Update on HBM Healthcare Investments AG's Equity Buyback Plan announced on July 5, 2023. CI
HBM Healthcare Investments Flags Fiscal H1 Loss MT
HBM Healthcare Investments AG Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
HBM Healthcare Investments' Ficsal Q1 NAV Per Share Declines MT
HBM Healthcare Investments AG commences an Equity Buyback Plan under the authorization approved on June 10, 2022. CI
HBM Healthcare's Portfolio Company Cathay Biotech to Sell Shares for CNY6.6 Billion MT
Kepler Cheuvreux Lowers Price Target on HBM Healthcare Investments, Maintains Buy Recommendation MT
HBM Healthcare Investments AG Reports Earnings Results for the Full Year Ended March 31, 2023 CI
HBM Healthcare Investments' Loss Widens in FY23 MT
HBM Healthcare Investments Posts 3% Drop in April NAV MT
HBM Healthcare Invests $12 Million into US-based ArriVent Biopharma MT
HBM Healthcare Investments CEO Set to Resume Duties After Health Issues MT
HBM Healthcare Investments' Portfolio Company Mineralys Therapeutics Completes $192 Million IPO MT
HBM Healthcare Investments CEO Takes Temporary Leave of Absence MT
HBM Healthcare Investments AG Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
HBM Healthcare Swings To Loss In Fiscal Q3 On Negative Currency Effects MT
HBM Healthcare Investments Flags Fiscal Nine-month Loss After NAV Dips MT
Chart HBM Healthcare Investments AG
More charts
HBM Healthcare Investments AG is a Switzerland-based venture capital company investing in emerging companies, mainly from the biotechnology and human medicine, diagnostics, as well as medical technology sectors. The Company focuses on unlisted companies, with two-thirds of assets being invested in private companies that offer high value-creation potential. As a holding company, it is involved in the acquisition, disposal and management of a diversified portfolio, as well as in financing and supporting the portfolio firms as a key partner. It focuses on companies with products either at an advanced stage of development or already available on the market. The primary investment areas are Western Europe and the United States. The Company's portfolio includes approximately 25 companies. As of March 31, 2012, the Company had six wholly owned subsidiaries, including three subsidiaries on Cayman Islands, two Barbados-based subsidiaries and a subsidiary in the United States.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
193.6 CHF
Average target price
236 CHF
Spread / Average Target
+21.90%
Consensus

Annual profits - Rate of surprise